Clearmind Medicine (Clearmind Medicine) Construction In Progress : $0.00 Mil (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine Construction In Progress?

Clearmind Medicine Construction In Progress Historical Data

The historical data trend for Clearmind Medicine's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine Construction In Progress Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Construction In Progress

Get a 7-Day Free Trial

Clearmind Medicine Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

Clearmind Medicine Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Clearmind Medicine (Clearmind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

CWY0:Germany CWY0:Germany CMND:Canada

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.